Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
U.S. cleaning and sanitation products major Ecolab Inc ( ECL - Analyst Report ) has divulged its plans to relocate its German offices and R&D operations from Dusseldorf to a new high-tech innovation center in Monheim am Rhein.
The new location will house the Minnesota-based company’s R&D, engineering as well as local sales and marketing functions. The Monheim am Rhein facility will have a world-class customer innovation center, where Ecolab’s innovative program and service solutions will be featured. The company is expected to commence relocating employees in November 2012. The completion of the move is expected in first-quarter 2013.
The company stated that its move to relocate its German facilities to the new center came at the right time as it celebrates the 50th anniversary of its presence in that country. Moreover, it has noted that the selection of the Monheim am Rhein location was based on its technical capabilities and additional space which will allow it to co-locate major functions.
Ecolab caters products and services to the hospitality, foodservice, institutional and industrial markets across more than 160 countries. The company’s U.S. Cleaning & Sanitizing and International divisions face stiff competition from Clorox ( CLX - Analyst Report ) and Church & Dwight ( CHD - Snapshot Report ) .
To drive growth, the company continues to invest in strategic areas such as, product innovation, healthcare, water and energy and global pest elimination while rationalizing operating costs.
Ecolab, in February 2011, announced a major restructuring plan for its European business aimed at boosting efficiency and profitability in that operation. As part of this initiative, the company plans to realign its supply chain and prune headcount which will involve elimination of roughly 900 jobs. The restructuring, once completed, has been projected to save more than $120 million annually.
Although we are impressed by Ecolab’s strong international exposure, we remain cautious about aggressive competition, raw material price fluctuations and dilutive impact of the hefty restructuring expenses on the company’s bottom line. We currently have a Neutral recommendation on Ecolab, which is backed by a Zacks #3 Rank (Hold).
Read the full reports :
Analyst Report on ECL
Snapshot Report on CHD
Analyst Report on CLX